Grifols SA (GRFS) Rating Lowered to Hold at Zacks Investment Research
Grifols SA (NASDAQ:GRFS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Shares of Grifols SA (NASDAQ:GRFS) traded up 0.06% on Wednesday, reaching $15.72. 536,961 shares of the company’s stock traded hands. The stock’s 50-day moving average price is $16.09 and its 200-day moving average price is $16.04. The stock has a market capitalization of $21.48 billion, a price-to-earnings ratio of 35.65 and a beta of 0.93. Grifols SA has a 52 week low of $14.07 and a 52 week high of $18.04.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/08/grifols-sa-grfs-rating-lowered-to-hold-at-zacks-investment-research.html
Large investors have recently modified their holdings of the company. Independent Portfolio Consultants Inc. raised its stake in shares of Grifols SA by 18.4% in the third quarter. Independent Portfolio Consultants Inc. now owns 11,140 shares of the company’s stock valued at $178,000 after buying an additional 1,730 shares during the last quarter. Hansberger Growth Investors LP raised its stake in shares of Grifols SA by 2.6% in the second quarter. Hansberger Growth Investors LP now owns 90,273 shares of the company’s stock valued at $1,505,000 after buying an additional 2,253 shares during the last quarter. Fiera Capital Corp bought a new stake in shares of Grifols SA during the second quarter valued at approximately $890,000. FDx Advisors Inc. raised its stake in shares of Grifols SA by 4.9% in the second quarter. FDx Advisors Inc. now owns 58,284 shares of the company’s stock valued at $972,000 after buying an additional 2,743 shares during the last quarter. Finally, Capital Guardian Trust Co. raised its stake in shares of Grifols SA by 2.2% in the second quarter. Capital Guardian Trust Co. now owns 421,336 shares of the company’s stock valued at $7,024,000 after buying an additional 9,103 shares during the last quarter. Institutional investors own 20.18% of the company’s stock.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Grifols SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA and related companies with MarketBeat.com's FREE daily email newsletter.